Prognostic Impact of Delta-haemolysin Production Deficiency in Staphylococcus Aureus on the Prognosis of Infected Implant Treated by DAIR

Recruiting

• Conditions: Bone and Joint Infection; Staphylococcus Aureus
• Interventions: Other: Delta-haemolysin

• Registration Number: NCT03796104
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

The aim of this study is to determine if delta-haemolysin production deficiency of Staphylococcus aureus is a marker in favour of chronic infections on implants

Detailed Description

Not available

Study Timeline

• Study Start: 2018-01-01
• Primary Completion: 2018-12-31
• Study First Submitted: 2019-01-04
• Study First Submitted QC: 2019-01-07
• Study First Posted: 2019-01-08
• Status Verified: 2023-04
• Last Update Submitted: 2023-04-12
• Last Update Posted: 2023-04-13
• Study Completion: 2023-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• patients having implant infection due to S. aureus treated by DAIR

Read More

Exclusion Criteria

• none

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Presence of delta-hemolysine	Delta-haemolysin	Implant infected by Staphylococcus aureus with delta-haemolysin Production
Deficiency of delta-hemolysine	Delta-haemolysin	Implant infected by Staphylococcus aureus with delta-haemolysin Production Deficiency

Primary Outcome Measures

Name	Time	Method
Rate of infection with or witout delta-haemolysin in Staphylococcus Aureus	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption	patients, profile of the bacterium, medical and chirurgical treatment, rate. comparison between the 2 groups

Secondary Outcome Measures

Name	Time	Method
Rate of Treatment Failure	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption	Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin. Analyse of risk factor. Comparison between the 2 groups

Trial Locations

Locations (1)

Hospices Civils de Lyon; 🇫🇷 Lyon, France